

Da Nang, August 14, 2026

*“Re: Explanation of Changes in Profit After
Corporate Income Tax in the Reviewed Interim
Financial Statements for the Six-Month Period Ended
30 June 2026 compared to the same period last year”*

**To: - State Securities Commission of Vietnam;
- Hanoi Stock Exchange.**

**1. Company name: Danang Pharmaceutical – Medical Equipment Joint Stock
Company**

2. Stock code: DDN (Upcom)

3. Head office: 02 Phan Dinh Phung, Hai Chau Ward, Danang City

4. Telephone: 0236.3822247

Published information content:

Pursuant to Circular No. 96/2020/TT-BTC dated November 16, 2020, Danang Pharmaceutical – Medical Equipment Joint Stock Company hereby provides the following explanation:

The profit after corporate income tax in the reviewed interim financial statements for the six-month period ended 30 June 2026 has increased/decreased by 10% or more compared with that of the same period in the previous year.:

Indicator	Interim Financial Statements for the Six-Month Period Ended 30 June 2026	Interim Financial Statements for the Six-Month Period Ended 30 June 2025	Difference (%)
Cumulative profit after corporate income tax for the six-month period	4,648,732,660 VND	1,266,434,672 VND	+ 267.1%

Details:

Profit after corporate income tax for the first six months of 2026 increased by 267.1% compared to the same period in 2025, mainly driven by growth in sales and improved operational efficiency across the Company’s core business segments compared to the same period in 2025.

Recipients:

- As above;
- Company website;
- Filed at Office.

DEPUTY GENERAL DIRECTOR



NGUYEN TRUNG